Stocks

Novo Nordisk Surges on Anthropic Collaboration and Hemophilia Treatment Approval

Guavy AI Editorial Team Published September 18, 2026

Instruments

AMZN

Novo Nordisk's stock price surged by 3.55% on Tuesday following its announcement of a strategic collaboration with AI firm Anthropic and positive regulatory developments for its hemophilia treatment in Europe.

The company has entered into an agreement to implement Anthropic's Claude Science platform, which is expected to accelerate drug development processes and enhance internal software capabilities. CEO Mike Doustdar emphasized that artificial intelligence can 'compress the path from research to marketed product' while unlocking new scientific avenues.

This collaboration marks another step in Novo's AI strategy, which includes previous partnerships with OpenAI and an established innovation center with Amazon Web Services. Industry-wide, the most tangible benefits from artificial intelligence have emerged in automating repetitive tasks such as data analysis, research synthesis, and clinical trial design.

Novo Nordisk Surges on Anthropic Collaboration and Hemophilia Treatment Approval

Google Locks Down Pixel Phones with New Quick Settings Security Feature

Google Simplifies Meeting Notes Creation in Calendar and Docs

Mediatek Tackles Memory Costs, Google Unfazed by $200 Billion Datacentre Bill